Literature DB >> 21872444

Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia.

Ronald R Seese1, Joseph O'Neill, Matthew Hudkins, Prabha Siddarth, Jennifer Levitt, Ben Tseng, Keng Nei Wu, Rochelle Caplan.   

Abstract

OBJECTIVE: Although magnetic resonance spectroscopy has identified metabolic abnormalities in adult and childhood schizophrenia, no prior studies have investigated the relationship between neurometabolites and thought disorder. This study examined this association in language-related brain regions using proton magnetic resonance spectroscopic imaging ((1)H MRSI).
METHOD: MRSI was acquired bilaterally from 28 youth with childhood-onset schizophrenia and 34 healthy control subjects in inferior frontal, middle frontal, and superior temporal gyri at 1.5T and short echo time (TR/TE = 1500/30 ms). CSF-corrected "total NAA" (tNAA; N-acetyl-aspartate + N-acetyl-aspartyl-glutamate), glutamate + glutamine (Glx), creatine + phosphocreatine (Cr + PCr), choline compounds (Cho), and myo-inositol (mI) were assayed in manually drawn regions-of-interest partitioned into gray matter, white matter, and CSF and then coregistered with MRSI. Speech samples of all subjects were coded for thought disorder.
RESULTS: In the schizophrenia group, the severity of formal thought disorder correlated significantly with tNAA in the left inferior frontal and superior temporal gyri and with Cr + PCr in left superior temporal gyrus.
CONCLUSIONS: Neurometabolite concentrations in language-related brain regions are associated with thought disorder in childhood-onset schizophrenia.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21872444      PMCID: PMC3229835          DOI: 10.1016/j.schres.2011.07.011

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  78 in total

Review 1.  Proton magnetic resonance spectroscopy in schizophrenia.

Authors:  A Bertolino; D R Weinberger
Journal:  Eur J Radiol       Date:  1999-05       Impact factor: 3.528

Review 2.  Linking Hebb's coincidence-detection to memory formation.

Authors:  J Z Tsien
Journal:  Curr Opin Neurobiol       Date:  2000-04       Impact factor: 6.627

3.  N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury.

Authors:  C Demougeot; P Garnier; C Mossiat; N Bertrand; M Giroud; A Beley; C Marie
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

4.  Abnormal object recall and anterior cingulate overactivation correlate with formal thought disorder in schizophrenia.

Authors:  Michal Assaf; Paul R Rivkin; Cheedem H Kuzu; Vince D Calhoun; Michael A Kraut; Karyn M Groth; Michael A Yassa; John Hart; Godfrey D Pearlson
Journal:  Biol Psychiatry       Date:  2005-09-30       Impact factor: 13.382

5.  Thought disorder: A developmental disability in pediatric epilepsy.

Authors:  Rochelle Caplan; Prabha Siddarth; Caroline E Bailey; Erin K Lanphier; Suresh Gurbani; W Donald Shields; Raman Sankar
Journal:  Epilepsy Behav       Date:  2006-05-05       Impact factor: 2.937

6.  Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia.

Authors:  Dieter F Braus; Gabriele Ende; Wolfgang Weber-Fahr; Traute Demirakca; Heike Tost; Fritz A Henn
Journal:  Eur Neuropsychopharmacol       Date:  2002-04       Impact factor: 4.600

7.  Findings of proton magnetic resonance spectometry in the dorsolateral prefrontal cortex in adolescents with first episodes of psychosis.

Authors:  Arantzazu Zabala; Javier Sánchez-González; Mara Parellada; Dolores María Moreno; Santiago Reig; María Teresa Burdalo; Olalla Robles; Manuel Desco; Celso Arango
Journal:  Psychiatry Res       Date:  2007-08-31       Impact factor: 3.222

8.  Neurochemical and structural correlates of executive dysfunction in schizophrenia.

Authors:  Nicolas Rüsch; Ludger Tebartz van Elst; Gabi Valerius; Martin Büchert; Thorsten Thiel; Dieter Ebert; Jürgen Hennig; Hans-Martin Olbrich
Journal:  Schizophr Res       Date:  2007-07-06       Impact factor: 4.939

Review 9.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

10.  3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia.

Authors:  Philip Tibbo; Chris Hanstock; Agitha Valiakalayil; Peter Allen
Journal:  Am J Psychiatry       Date:  2004-06       Impact factor: 18.112

View more
  16 in total

1.  Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial.

Authors:  Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi
Journal:  Neuropsychopharmacology       Date:  2017-04-04       Impact factor: 7.853

2.  Differential neuroimaging indices in prefrontal white matter in prenatal alcohol-associated ADHD versus idiopathic ADHD.

Authors:  Joseph O'Neill; Mary J O'Connor; Victor Yee; Ronald Ly; Katherine Narr; Jeffrey R Alger; Jennifer G Levitt
Journal:  Birth Defects Res       Date:  2019-01-29       Impact factor: 2.344

Review 3.  Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.

Authors:  Eva-Margarete Spur; Emily A Decelle; Leo L Cheng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-03       Impact factor: 9.236

4.  MRSI correlates of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.

Authors:  Joseph O'Neill; John C Piacentini; Susanna Chang; Jennifer G Levitt; Michelle Rozenman; Lindsey Bergman; Noriko Salamon; Jeffry R Alger; James T McCracken
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-10-01       Impact factor: 5.067

Review 5.  Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

Authors:  Eline M P Poels; Lawrence S Kegeles; Joshua T Kantrowitz; Daniel C Javitt; Jeffrey A Lieberman; Anissa Abi-Dargham; Ragy R Girgis
Journal:  Schizophr Res       Date:  2014-01-11       Impact factor: 4.939

6.  1H MRSI of middle frontal gyrus in pediatric ADHD.

Authors:  Sharwin Tafazoli; Joseph O'Neill; Anthony Bejjani; Ronald Ly; Noriko Salamon; James T McCracken; Jeffry R Alger; Jennifer G Levitt
Journal:  J Psychiatr Res       Date:  2012-12-27       Impact factor: 4.791

7.  Effects of intensive cognitive-behavioral therapy on cingulate neurochemistry in obsessive-compulsive disorder.

Authors:  Joseph O'Neill; Eda Gorbis; Jamie D Feusner; Jenny C Yip; Susanna Chang; Karron M Maidment; Jennifer G Levitt; Noriko Salamon; John M Ringman; Sanjaya Saxena
Journal:  J Psychiatr Res       Date:  2013-01-04       Impact factor: 4.791

8.  Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: a proton magnetic resonance spectroscopy study.

Authors:  M I Atagün; E M Şıkoğlu; S S Can; G Karakaş-Uğurlu; S Ulusoy-Kaymak; A Çayköylü; O Algın; M L Phillips; C M Moore; D Öngür
Journal:  Schizophr Res       Date:  2014-12-03       Impact factor: 4.939

9.  1H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease.

Authors:  Elizabeth Joe; Luis D Medina; John M Ringman; Joseph O'Neill
Journal:  Brain Imaging Behav       Date:  2019-08       Impact factor: 3.978

10.  Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.

Authors:  Camilo de la Fuente-Sandoval; Pablo León-Ortiz; Mariana Azcárraga; Sylvana Stephano; Rafael Favila; Leonardo Díaz-Galvis; Patricia Alvarado-Alanis; Jesús Ramírez-Bermúdez; Ariel Graff-Guerrero
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.